Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Oncology

Background:

• Co-inhibitory receptors on T cells regulate immune responses and maintain self-tolerance.
• Malignancies exploit co-inhibitory pathways to evade anti-tumour immunity.
• Targeting these pathways can unleash endogenous immune responses against cancer.

Purpose of the Study:

• To review the mechanisms and expression patterns of co-inhibitory receptors on T cell subsets.
• To summarize recent clinical findings in immune checkpoint blockade therapy.

Main Methods:

• Review of existing literature on co-inhibitory receptors and immune checkpoint blockade.
• Analysis of T cell subsets (CD4+ and CD8+) and their co-inhibitory receptor expression.
• Summary of clinical trial outcomes for therapies targeting CTLA-4 and PD-1 pathways.

Main Results:

• Co-inhibitory receptors negatively regulate T cell activation, crucial for self-tolerance.
• Ligands for these receptors are upregulated in cancers, facilitating immune evasion.
• Antibodies blocking co-inhibitory interactions show promising clinical responses.

Conclusions:

• Immune checkpoint blockade therapies, targeting pathways like CTLA-4 and PD-1, offer a promising strategy to enhance anti-tumour immunity.
• Understanding co-inhibitory receptor function on different T cell subsets is key to optimizing cancer immunotherapy.
• Further research into co-inhibitory receptor mechanisms can lead to improved cancer treatments.